Long-acting injectable antipsychotic use in patients with bipolar disorder: Findings from the REAP-BD study
Issued Date
2025-01-01
Resource Type
ISSN
18762018
eISSN
18762026
Scopus ID
2-s2.0-85211243394
Journal Title
Asian Journal of Psychiatry
Volume
103
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Journal of Psychiatry Vol.103 (2025)
Suggested Citation
Lin C., Lin Y.P., Park S.C., Jang O.J., Si T.M., Xiang Y.T., Lin H.L., Javed A., Sayeed Khan M.N., Grover S., Kallivayali R.A., Chee K.Y., Kato T.A., Pariwatcharakul P., Maramis M., Seneviratne L., Sim K., Tang W.K., Oo T., Sartorius N., Tan C.H., Mian-Yoon, Shinfuku N., Lin S.K. Long-acting injectable antipsychotic use in patients with bipolar disorder: Findings from the REAP-BD study. Asian Journal of Psychiatry Vol.103 (2025). doi:10.1016/j.ajp.2024.104338 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102906
Title
Long-acting injectable antipsychotic use in patients with bipolar disorder: Findings from the REAP-BD study
Author's Affiliation
Faculty of Health Sciences
Siriraj Hospital
Graduate School of Medical Sciences
Peking University Sixth Hospital
University of Sri Jayewardenepura
Hanyang University Guri Hospital
University of Yangon
Services Institute of Medical Sciences Lahore
Universitas Airlangga
Chang Gung Memorial Hospital
Hanyang University College of Medicine
Taipei City Hospital Taiwan
Kuala Lumpur Hospital
Seinan Gakuin University
National University of Singapore
Singapore Institute of Mental Health
Chinese University of Hong Kong
Postgraduate Institute of Medical Education and Research, Chandigarh
Singapore; Regency Specialist Hospital
Pushpagiri Institute of Medical Sciences
Association for the Improvement of Mental Health Programs
Pakistan Psychiatric Research Centre
Bugok National Hospital
Siriraj Hospital
Graduate School of Medical Sciences
Peking University Sixth Hospital
University of Sri Jayewardenepura
Hanyang University Guri Hospital
University of Yangon
Services Institute of Medical Sciences Lahore
Universitas Airlangga
Chang Gung Memorial Hospital
Hanyang University College of Medicine
Taipei City Hospital Taiwan
Kuala Lumpur Hospital
Seinan Gakuin University
National University of Singapore
Singapore Institute of Mental Health
Chinese University of Hong Kong
Postgraduate Institute of Medical Education and Research, Chandigarh
Singapore; Regency Specialist Hospital
Pushpagiri Institute of Medical Sciences
Association for the Improvement of Mental Health Programs
Pakistan Psychiatric Research Centre
Bugok National Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Aims: This study aimed to assess treatment patterns and the effectiveness of long-acting injectable antipsychotics (LAIs) in patients with bipolar disorder (BD) across various Asian countries. The study focused on comparing the choices of LAIs, other psychotropic medications, and their psychotropic drug load to explore real-world usage and evaluate the potential benefits of LAIs in BD treatment across different countries. Methods: A retrospective cohort study was conducted with BD patients diagnosed according to ICD-10-CM codes F31.0 to F31.9 across 13 Asian countries or regions. Data were collected through an online system covering prescriptions for all psychotropic medications including LAIs. The Anatomical Therapeutic Chemical (ATC) Classification System was used to compare medication dosage patterns. Results: The study analyzed 2029 prescription records for BD, including 103 cases involving LAIs. The highest LAI prescription rates were found in Sri Lanka and Malaysia, with no reported use in Myanmar, India, and Japan. Patients receiving LAIs were younger, more often male, and had higher BMI and drug loads compared to those on oral medications. South Korea and Indonesia showed the highest LAIs drug load. South Korea, Pakistan, and China exhibited the highest total psychotropic drug loads, while Malaysia had the lowest. Conclusions: This study is the first to examine LAIs use for BD across Asia. Cross-national differences in LAIs prescriptions and psychotropic drug load highlight variations in treatment practices and healthcare systems. These findings underscore the need for further research and the development of region-specific guidelines to improve BD treatment outcomes.
